Japanese encephalitis virus vaccine

(redirected from Ixiaro)

Japanese encephalitis virus vaccine

(Ja-pan-ees en-se-fa-li-tes vak-seen) ,

Ixiaro

(trade name)

Classification

Therapeutic: vaccines immunizing agents
Pregnancy Category: B

Indications

Active immunization against disease caused by Japanese encephalitis virus (JEV) in persons ≥17 yr.

Action

An inactive form of the virus induces antibodies that neutralize live JEV.

Therapeutic effects

Prevention of disease caused by JEV.

Pharmacokinetics

Absorption: Absorption follows intramuscular administration.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (antibody production)

ROUTEONSETPEAKDURATION
IMunknownwithin 10 daysunknown

Contraindications/Precautions

Contraindicated in: Serious hypersensitivity to a previous dose; Serious hypersensitivity to protamine.
Use Cautiously in: Immunocompromised patients (may have ↓ response); Obstetric / Lactation: Safety and effectiveness not established; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • headache (most frequent)

Local

  • pain (most frequent)
  • tenderness (most frequent)
  • edema
  • pruritus

Musculoskeletal

  • myalgia (most frequent)

Interactions

Drug-Drug interaction

Concurrent use of immunosuppressives including antineoplastics and corticosteroids may ↓ antibody reponse and ↑ risk of adverse reactions.

Route/Dosage

Intramuscular (Adults ≥17 yr) 0.5 mL, repeated 28 days later; series completed at least 1 wk prior to potential exposure to JEV.

Availability

Suspension for injection (contains protamine): 0.5 mL single dose syringes

Nursing implications

Nursing assessment

  • Determine if patient has had reactions to previous vaccines.
  • Obtain temperature. Vaccine should not be administered to patients with fever >100°F.

Potential Nursing Diagnoses

Risk for infection (Indications)

Implementation

  • Immunization is administered in 2 doses, 28 days apart, completed at least 1 wk prior to exposure to JEV.
  • Intramuscular: Store in refrigerator; clear liquid with white precipitation may form during storage. Shake syringe well to obtain a white, opaque, homogenous suspension. Do not administer if discolored or contains particulate matter. Inject into deltoid; do not give intravenously, intradermally or subcutaneously.

Patient/Family Teaching

  • Inform patient of the purpose of vaccine and that vaccine is non-infectious. If second dose is missed, contact health care professional to determine when to receive second dose. Maximum protection is not achieved until 1 wk after second dose. Advise patient to read Patient Information Sheet prior to vaccination.
  • Advise patient of precautions to take to reduce exposure to mosquito bites transmitting virus (adequate clothing, use of repellents, mosquito nets). Vaccine may not fully protect everyone who gets the vaccine, does not protect against other types of encephalitis or other diseases transmitted by mosquito bites.
  • Advise patient to tell health care professional what medications they are taking.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

  • Protection against Japanese Encephalitis Virus.
References in periodicals archive ?
These vaccines include Prevnar/ Prevnar 13, Gardasil/ Gardasil 9, Vaxigrip, Fluzone, Flublok, Varivax, Proquad, Menactra, Fluarix/ FluLaval, Pneumovax 23, Havrix/ Twinrix/ Engerix-B, Priorix, Priorix Tetra, Varilrix, M-M-R II, Adacel, Boostrix, Menveo, Bexsero, Cervarix, Shingrix, Trumenba, Rotateq, Pentacel, Pentaxim, Imovax, Hexaxim, Zostavax, Rotarix, Sunflorix, Pediarix, Infanrix, Ticovac, Biken Ha, Tetrabik, Mearubik, Varicella (MTP), Jebik V, Flumist/ Fluenz, Bio Thrax, Dukoral, In Live, Ixiaro, HeaLive, In Live, BiLive, EasySix, Imvamune, and Anflu.
Valneva USA, which is based in Gaithersburg, received approval last week for an alternate immunization schedule of Ixiaro, the only vaccine approved in America for protection against the virus, the company announced.
(SeeNews) - Aug 8, 2014 - Biotechnology company Valneva SE (EPA:VLA), a tie-up of Austrian Intercell and French Vivalis, narrowed its first-half net loss by EUR 9.8 million to EUR 12.2 million (USD 16.34m) thanks to higher profitability of the Ixiaro vaccine and merger synergies.
Since 2009, a vaccine of inactivated JE virus derived from Vero cell culture (Ixiaro, manufactured by Intercell Biomedical and distributed by Norvartis) has been available in the United States for adults [greater than or equal to] 17 years who travel during JE virus transmission season to parts of Asia where the virus is endemic.
On June 19, 2013, the Advisory Committee on Immunization Practices (ACIP) voted to extend existing recommendations for use of inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) (Ixiaro, Intercell Biomedical) to include children aged 2 months through 16 years (1).
The JE-VC vaccine, manufactured as IXIARO, was licensed for use in adults in the United States, Europe, and Australia in 2009.
However, JEEV / Ixiaro would have the advantage of prior FDA approval making it a more confident choice for travelers from Europe/ America.
(ADPnews) - May 27, 2011 - Austrian vaccine maker Intercell AG (WBAG:ICLL) is recalling batch JEV09L37 of the Ixiaro vaccine throughout the EU, European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) said today.
In March 2009, the Food and Drug Administration licensed a new Japanese encephalitis vaccine, Intercell's Ixiaro (distributed by Novartis), for use in adults aged 17 years and older.
market: Ilaris, Reclast, Afinitor, Ixiaro, Exforge HCT, and Coartem.
The vaccine, called Ixiaro, prevents Japanese encephalitis (JE), which causes 10,000 to 15,000 deaths each year.
The vaccine is marketed as Ixiaro by Intercell Biomed, a Scottish company, and is distributed in the United States by Novartis.